扩大CGM可及性对参加医疗补助计划的糖尿病患者使用率的影响
这项回顾性队列研究纳入美国医疗补助计划中完全补贴CGM的3,036名成人糖尿病患者,评估CGM使用率、依从性及HbA1c变化;结果显示1型与2型糖尿病患者的填充依从性相似(平均MPR 0.78 vs. 0.72;P=0.06),主要种族/族裔组间CGM使用率无显著差异,2型糖尿病患者使用CGM与HbA1c改善相关(-1.2% [13.1 mmol/mol];P<0.001)。
要点
- 完全补贴CGM后,1型与2型糖尿病患者的填充依从性相似(平均MPR 0.78 vs. 0.72;P=0.06)。
- 主要种族/族裔组间CGM使用率无显著差异。
- 2型糖尿病患者使用CGM与HbA1c改善相关(-1.2% [13.1 mmol/mol];P<0.001)。
核心结论
- 消除CGM费用障碍可在很大程度上克服CGM使用差异,且CGM使用与所有主要种族/族裔组的HbA1c改善相关。
研究设计与样本
- 回顾性队列研究,纳入美国医疗补助计划中完全补贴CGM的3,036名成人糖尿病患者。
主要发现
- 1型与2型糖尿病患者的CGM填充依从性相似(平均MPR 0.78 vs. 0.72;P=0.06)。
- 主要种族/族裔组间CGM使用率无显著差异。
- 2型糖尿病患者使用CGM与HbA1c改善相关(-1.2% [13.1 mmol/mol];P<0.001),且主要种族/族裔组间可比。
- 填充依从性较高者HbA1c降低幅度大于依从性较低者(-1.4% [15.3 mmol/mol] vs. -1.0% [10.9 mmol/mol];P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Current studies on continuous glucose monitor (CGM) uptake are revealing for significant barriers and inequities for CGM use among patients from socially underprivileged communities. This study explores the effect of full subsidies regardless of diabetes type on CGM uptake and HbA1c outcomes in a U.S. adult patient population on Medicaid. RESEARCH DESIGN AND METHODS: This retrospective cohort study examined 3,036 adults with diabetes enrolled in a U.S. Medicaid program that fully subsidized CGM. CGM uptake and adherence were assessed by CGM prescription and dispense data, including more than one fill and adherence by medication possession ratio (MPR). Multivariate logistic regression evaluated predictors of CGM uptake. Pre- and post-CGM use HbA1c were compared. RESULTS: CGM were very well received by both individuals with type 1 diabetes and individuals with type 2 diabetes with similar high fill adherence levels (mean MPR 0.78 vs. 0.72; P = 0.06). No significant difference in CGM uptake outcomes were noted among major racial/ethnic groups. CGM use was associated with improved HbA1c among those with type 2 diabetes (-1.2% [13.1 mmol/mol]; P < 0.001) that was comparable between major racial/ethnic groups and those with higher fill adherence achieved greater HbA1c reduction (-1.4% [15.3 mmol/mol]; P < 0.001) compared with those with lower adherence (-1.0% [10.9 mmol/mol]; P < 0.001). CONCLUSIONS: CGM uptake disparities can largely be overcome by eliminating CGM cost barriers. CGM use was associated with improved HbA1c across all major racial/ethnic groups, highlighting broad CGM appeal, utilization, and effectiveness across an underprivileged patient population.
引用
- Ni K, Tampe CA, Sol K, et al. Effect of CGM Access Expansion on Uptake Among Patients on Medicaid With Diabetes. Diabetes Care. 2023. PMID: 36480729. doi:10.2337/dc22-1287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。